A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Conditions: COPD (Chronic Obstructive Pulmonary Disease) Interventions: Drug: BGF MDI 320/14.4/9.6 μg; Drug: GFF MDI 14.4/9.6 μg Sponsors: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cardiology | Chronic Obstructive Pulmonary | Heart | Research | Study | Symbicort